R&D channel feed

J&J re­ports dura­bil­i­ty da­ta for blad­der can­cer 'pret­zel' drug af­ter FDA fil­ing

17 hours ago

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Yesterday
Pharma
FDA+

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

Yesterday
China

Hop­ing to turn CD47 around with Keytru­da com­bo, ALX On­col­o­gy re­ports two Phase 2 fail­ures

Yesterday

Cari­bou lays off 32% of staff, cuts lu­pus cell ther­a­py pro­gram be­fore first pa­tient

2 days ago
People
Cell/Gene Tx

Sanofi's Al­tuvi­i­io clos­ing in on block­buster sta­tus, Dupix­ent sales surge

3 days ago
Pharma

As­cle­tis posts puz­zling Phase 1 up­date on obe­si­ty pill

3 days ago

Ake­so re­ports an­oth­er Phase 3 win for PD-1xVEGF ap­proach in lung can­cer

3 days ago

Boehringer taps Dutch biotech for ALT pos­i­tive can­cer pact ex­ceed­ing $573M in biobucks

4 days ago
Deals

Bris­tol My­er­s' schiz­o­phre­nia drug fails Phase 3 tri­al for ad­junc­tive treat­ment

4 days ago
Pharma

As­traZeneca, Dai­ichi eye first-line breast can­cer mar­ket af­ter En­her­tu's ear­ly Phase 3 win

5 days ago
Pharma

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

5 days ago
Startups
China

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

5 days ago

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

6 days ago
People

Roche dis­con­tin­ues low dose in Hunt­ing­ton’s tri­al, will switch pa­tients to high dose

Last week

Nether­lands pours $1.5B in­to biotech in pur­suit of glob­al lead­er­ship am­bi­tions

Last week
Financing

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Last week

CDC ad­vi­sors broad­en RSV vac­cine rec­om­men­da­tions to at-risk adults in their 50s

Last week

Gly­comine rais­es $115M to see if it can treat rare gly­co­sy­la­tion dis­or­der

Last week
Financing
Startups

Mur­al On­col­o­gy ends clin­i­cal de­vel­op­ment, lays off most work­ers

Last week
People

Sanofi’s Kymab-orig­i­nat­ed in­flam­ma­to­ry drug flunks mid-stage asth­ma tri­al

Last week

FDA clears clin­i­cal tri­al of gene-edit­ed pig liv­er used out­side of body

Last week

Mer­ck ex­plores po­ten­tial of oral pep­tides in deal with Aus­tri­an biotech

Last week
Deals

Sid­dhartha Mukher­jee’s cell ther­a­py start­up nar­rows fo­cus as staff shrinks

Last week
Cell/Gene Tx
1234 Next page Last page
A service from the Financial Times